Long-lasting enfuvirtide carrier pentasaccharide conjugates with potent anti-human immunodeficiency virus type 1 activity

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 1, 2010, Pages 134-142

  Huet, Thierry ^a   Kerbarh, Olivier ^a   Schols, Dominique ^b   Clayette, Pascal ^c   Gauchet, Cécile ^a   Dubreucq, Guy ^d   Vincent, Loïc ^d   Bompais, Heidi ^d   Mazinghien, Romain ^d   Querolle, Olivier ^a   Salvador, Arnaud ^e   Lemoine, Jérôme ^e   Lucidi, Bruno ^a   Balzarini, Jan ^b   Petitou, Maurice ^a  

^a Endotis Pharma   (France)

^b REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^c INSTITUT DE RADIOPROTECTION ET DE SÛRETÉ NUCLÉAIRE   (France)

^d Endotis Pharma   (France)

^e UNIVERSITÉ LYON 1   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ENFUVIRTIDE; EP 40111; EP 40112; MACROGOL; MARAVIROC; PENTASACCHARIDE; PLERIXAFOR; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BINDING; DRUG BLOOD LEVEL; DRUG DESIGN; DRUG HALF LIFE; DRUG STRUCTURE; DRUG SYNTHESIS; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IC 50; IN VITRO STUDY; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 73849105973     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00827-09     Document Type: Article

References (59)

1. Adachi, A., H. E. Gendelman, S. Koenig, T. Folks, R. Willey, A. Rabson, and M. A. Martin. 1986. Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J. Virol. 59:284-291.
2. Bai, Y., and W. C. Shen. 2006. Improving the oral efficacy of recombinant granulocyte colony-stimulating factor and transferrin fusion protein by spacer optimization. Pharm. Res. 23:2116-2121.
3. Bailon, P. S., and C. Y. Won. 23 May 2006. Pegylated T20 polypeptide. U.S. patent 7, 049, 415.
4. Ball, R. A., and T. Kinchelow. 2003. Injection site reactions with the HIV-1 fusion inhibitor enfuvirtide. J. Am. Acad. Dermatol. 49:826-831.
5. Balzarini, J., S. Hatse, K. Vermeire, K. Princen, S. Aquaro, C. F. Perno, E. De Clercq, H. Egberink, G. Vanden Mooter, W. Peumans, E. Van Damme, and D. Schols. 2004. Mannose-specific plant lectins from the Amaryllidaceae family qualify as efficient microbicides for prevention of human immunodeficiency virus infection. Antimicrob. Agents Chemother. 48:3858-3870.
6. Balzarini, J., K. Van Laethem, S. Hatse, K. Vermeire, E. De Clercq, W. Peumans, E. Van Damme, A. M. Vandamme, A. Bölmstedt, and D. Schols. 2004. Profile of resistance of human immunodeficiency virus to mannosespecific plant lectins. J. Virol. 78:10617-10627.
7. Barré-Sinoussi, F., J. C. Chermann, F. Rey, M. T. Nugeyre, S. Chamaret, J. Gruest, C. Dauguet, C. Axler-Blin, F. Vézinet-Brun, C. Rouzioux, W. Rozenbaum, and L. Montagnier. 1983. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 220:868-871.
8. Beals, J. M., and A. B. Shanafelt. 2006. Enhancing exposure of protein therapeutics. Drug Discov. Today Technol. 3:87-94.
9. Björk, I., and S. T. Olson. 1997. Antithrombin. A bloody important serpin, p. 17-33. In F. C. Church, D. D. Cunningham, D. Ginsburg, M. Hoffman, S. R. Stone, and D. M. Tollefsen (ed.), Chemistry and biology of serpins. Plenum Press, New York, NY.
10. Briz, V., E. Poveda, and V. Soriano. 2006. HIV entry inhibitors: mechanisms of action and resistance pathways. J. Antimicrob. Chemother. 57:619-627.
11. Buijsman, R. C., J. E. Basten, T. G. Van Dinther, G. A. Van der Marel, C. A. Van Boeckel, and J. H. Van Boom. 1999. Design and synthesis of a novel synthetic NAPAP-penta-saccharide conjugate displaying a dual antithrombotic action. Bioorg. Med. Chem. Lett. 9:2013-2018.
12. Chan, D. C., and P. S. Kim. 1998. HIV entry and its inhibition. Cell 93:681-684.
13. Chang, D., S. J. Kolis, K. H. Linderholm, T. F. Julian, R. Nachi, A. M. Dzerk, P. P. Lin, J. W. Lee, and S. K. Bansal. 2005. Bioanalytical method development and validation for a large peptide HIV fusion inhibitor (enfuvirtide, T-20) and its metabolite in human plasma using LC-MS/MS. J. Pharm. Biomed. Anal. 38:487-496.
14. Chuang, V. T., U. Kragh-Hansen, and M. Otagiri. 2002. Pharmaceutical strategies utilizing recombinant human serum albumin. Pharm. Res. 19:569-577.
15. de Kort, M., B. Gianotten, J. A. Wisse, E. S. Bos, M. H. Eppink, E. Mattaar, G. M. Vogel, W. H. Dokter, M. Honing, S. Vonsovic, M. J. Smit, J. C. Wijkmans, and C. A. Van Boeckel. 2008. Conjugation of ATIII-binding pentasaccharides to extend the half-life of proteins: long-acting insulin. Chem. Med. Chem. 3:1189-1193.
16. Doms, R. W., and D. Trono. 2000. The plasma membrane as a combat zone in the HIV battlefield. Genes Dev. 14:2677-2688.
17. Dorr, P., M. Westby, S. Dobbs, P. Griffin, B. Irvine, M. Macartney, J. Mori, G. Rickett, C. Smith-Burchnell, C. Napier, R. Webster, D. Armour, D. Price, B. Stammen, A. Wood, and M. Perros. 2005. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob. Agents Chemother. 49:4721-4732.
18. Eckert, D. M., and P. S. Kim. 2001. Mechanisms of viral membrane fusion and its inhibition. Annu. Rev. Biochem. 70:777-810.
19. Eckert, D. M., Y. Shi, S. Kim, B. D. Welch, E. Kang, E. S. Poff, and M. S. Kay. 2008. Characterization of the steric defense of the HIV-1 gp41 N-trimer region. Protein Sci. 17:2091-2100.
20. Flexner, C. 2007. HIV drug development: the next 25 years. Nat. Rev. Drug Discov. 6:959-966.
21. Freed, E. O., and M. A. Martin. 1995. The role of human immunodeficiency virus type 1 envelope glycoproteins in virus infection. J. Biol. Chem. 270: 23883-23886.
22. Gallo, R. C., P. S. Sarin, E. P. Gelmann, M. Robert-Guroff, E. Richardson, V. S. Kalyanaraman, D. Mann, G. D. Sidhu, R. E. Stahl, S. Zolla-Pazner, J. Leibowitch, and M. Popovic. 1983. Isolation of human T-cell leukemia virus in acquired immune deficiency syndrome (AIDS). Science 220:865-867.
23. Garber, A. J. 2005. Pharmacologic modifications of hormones to improve their therapeutic potential for diabetes management. Diabetes Obes. Metab. 7:666-674.
24. Gettins, P. G. 2002. Serpin structure, mechanism, and function. Chem. Rev. 102:4751-4804.
25. Goffinet, C., I. Allespach, and O. T. Keppler. 2007. HIV-susceptible transgenic rats allow rapid preclinical testing of antiviral compounds targeting virus entry or reverse transcription. Proc. Natl. Acad. Sci. U. S. A. 104:1015-1020.
26. Harris, J. M., and R. B. Chess. 2003. Effect of pegylation on pharmaceuticals. Nat. Rev. Drug Discov. 2:214-221.
27. Harrison, S. C. 2005. Mechanism of membrane fusion by viral envelope proteins. Adv. Virus Res. 64:231-261.
28. Herbert, J. M., J. P. Hérault, A. Bernat, R. G. Van Amsterdam, J. C. Lormeau, M. Petitou, C. Van Boeckel, P. Hoffmann, and D. G. Meuleman. 1998. Biochemical and pharmacological properties of SANORG 34006, a potent and long-acting synthetic pentasaccharide. Blood 91:4197-4205.
29. Kilby, J. M., S. Hopkins, T. M. Venetta, B. DiMassimo, G. A. Cloud, J. Y. Lee, L. Alldredge, E. Hunter, D. Lambert, D. Bolognesi, T. Matthews, M. R. Johnson, M. A. Nowak, G. M. Shaw, and M. S. Saag. 1998. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat. Med. 4:1302-1307.
30. Kilby, J. M., J. P. Lalezari, J. J. Eron, M. Carlson, C. Cohen, R. C. Arduino, J. C. Goodgame, J. E. Gallant, P. Volberding, R. L. Murphy, F. Valentine, M. S. Saag, E. L. Nelson, P. R. Sista, and A. Dusek. 2002. The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults. AIDS Res. Hum. Retrovir. 18:685-693.
31. Krambovitis, E., F. Porichis, and D. A. Spandidos. 2005. HIV entry inhibitors: a new generation of antiretroviral drugs. Acta Pharmacol. Sin. 26:1165-1173.
32. Lalezari, J. P., J. J. Eron, M. Carlson, C. Cohen, E. DeJesus, R. C. Arduino, J. E. Gallant, P. Volberding, R. L. Murphy, F. Valentine, E. L. Nelson, P. R. Sista, A. Dusek, and J. M. Kilby. 2003. A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy. AIDS 17:691-698.
33. Lazzarin, A., B. Clotet, D. Cooper, J. Reynes, K. Arasteh, M. Nelson, C. Katlama, H. J. Stellbrink, J. F. Delfraissy, J. Lange, L. Huson, R. DeMasi, C. Wat, J. Delehanty, C. Drobnes, and M. Salgo. 2003. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N. Engl. J. Med. 348:2186-2195.
34. Leader, B., Q. J. Baca, and D. E. Golan. 2008. Protein therapeutics: a summary and pharmacological classification. Nat. Rev. Drug Discov. 7:21-39.
35. Low, S. C., S. L. Nunes, A. J. Bitonti, and J. A. Dumont. 2005. Oral and pulmonary delivery of FSH-Fc fusion proteins via neonatal Fc receptor-mediated transcytosis. Hum. Reprod. 20:1805-1813.
36. Lu, J., S. G. Deeks, R. Hoh, G. Beatty, B. A. Kuritzkes, J. N. Martin, and D. R. Kuritzkes. 2006. Rapid emergence of enfuvirtide resistance in HIV-1-infected patients: results of a clonal analysis. J. Acquir. Immune Defic. Syndr. 43:60-64.
37. Ma, Q., and J. Fareed. 2004. Idraparinux sodium. Sanofi-Aventis. IDrugs 7:1028-1034.
38. Maggi, P., N. Ladisa, E. Cinori, A. Altobella, G. Pastore, and R. Filotico. 2004. Cutaneous injection site reactions to long-term therapy with enfuvirtide. J. Antimicrob. Chemother. 53:678-681.
39. Matthews, T., M. Salgo, M. Greenberg, J. Chung, R. DeMasi, and D. Bolognesi. 2004. Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes. Nat. Rev. Drug Discov. 3:215-225.
40. Myers, S. A., A. A. Selim, M. A. McDaniel, R. Hall, Y. Zhang, J. A. Bartlett, and A. L. True. 2006. A prospective clinical and pathological examination of injection site reactions with the HIV-1 fusion inhibitor enfuvirtide. Antivir. Ther. 11:935-939.
41. Naicker, K. P., H. Li, A. Heredia, H. Song, and L. X. Wang. 2004. Design and synthesis of alpha Gal-conjugated peptide T20 as novel antiviral agent for HIV-immunotargeting. Org. Biomol. Chem. 2:660-664.
42. Orloff, S. L., M. S. Kennedy, A. A. Belperron, P. J. Maddon, and J. S. McDougal. 1993. Two mechanisms of soluble CD4 (sCD4)-mediated inhibition of human immunodeficiency virus type 1 (HIV-1) infectivity and their relation to primary HIV-1 isolates with reduced sensitivity to sCD4. J. Virol. 67:1461-1471.
43. Petitou, M., and C. A. Van Boeckel. 2004. A synthetic antithrombin III binding pentasaccharide is now a drug! What comes next? Angew. Chem. Int. Ed. Engl. 43:3118-3133.
44. Reeves, J. D., F. H. Lee, J. L. Miamidian, C. B. Jabara, M. M. Juntilla, and R. W. Doms. 2005. Enfuvirtide resistance mutations: impact on human immunodeficiency virus envelope function, entry inhibitor sensitivity, and virus neutralization. J. Virol. 79:4991-4999.
45. Roberts, M. J., M. D. Bentley, and J. M. Harris. 2002. Chemistry for peptide and protein PEGylation. Adv. Drug Deliv. Rev. 54:459-476.
46. Roisin, A., J. P. Robin, N. Dereuddre-Bosquet, A. L. Vitte, D. Dormont, P. Clayette, and P. Jalinot. 2004. Inhibition of HIV-1 replication by cell-penetrating peptides binding. Rev. J. Biol. Chem. 279:9208-9214.
47. Schols, D., S. Struyf, J. Van Damme, J. A. Este, G. Henson, and E. De Clercq. 1997. Inhibition of T-tropic HIV strains by selective antagonization of the chemokine receptor CXCR4. J. Exp. Med. 186:1383-1388.
48. Sinclair, A. M., and S. Elliott. 2005. Glycoengineering: the effect of glycosylation on the properties of therapeutic proteins. J. Pharm. Sci. 94:1626-1635.
49. Stocker, H., C. Kloft, N. Plock, A. Breske, G. Kruse, C. Herzmann, H. Schulbin, P. Kreckel, C. Weber, F. Goebel, J. Roeling, S. Staszewski, A. Plettenberg, C. Moecklinghoff, K. Arasteh, and M. Kurowski. 2006. Pharmacokinetics of enfuvirtide in patients treated in typical routine clinical settings. Antimicrob. Agents Chemother. 50:667-673.
50. Stoddart, C. A., G. Nault, S. A. Galkina, K. Thibaudeau, P. Bakis, N. Bousquet-Gagnon, M. Robitaille, M. Bellomo, V. Paradis, P. Liscourt, A. Lobach, M. E. Rivard, R. G. Ptak, M. K. Mankowski, D. Bridon, and O. Quraishi. 2008. Albumin-conjugated C34 peptide HIV-1 fusion inhibitor: equipotent to C34 and T-20 in vitro with sustained activity in SCID-hu Thy/Liv mice. J. Biol. Chem. 283:34045-34052.
51. Van Amsterdam, R. G., G. M. Vogel, A. Visser, W. J. Kop, M. T. Buiting, and D. G. Meuleman. 1995. Synthetic analogues of the antithrombin III-binding pentasaccharide sequence of heparin. Prediction of in vivo residence times. Arterioscler. Thromb. Vasc. Biol. 15:495-503.
52. Van den Broek, I., R. W. Sparidans, J. H. Schellens, and J. H. Beijnen. 2007. Enzymatic digestion as a tool for the LC-MS/MS quantification of large peptides in biological matrices: measurement of chymotryptic fragments from the HIV-1 fusion inhibitor enfuvirtide and its metabolite M-20 in human plasma. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 854: 245-259.
53. Veronese, F. M., and G. Pasut. 2005. PEGylation, successful approach to drug delivery. Drug Discov. Today 10:1451-1458.
54. Walenga, J. M., W. P. Jeske, and J. Fareed. 2005. Short- and long-acting synthetic pentasaccharides as antithrombotic agents. Expert Opin. Investig. Drugs 14:847-858.
55. Weitz, J. I. 2004. New anticoagulants for treatment of venous thromboembolism. Circulation 110:I19-I26.
56. Werle, M., and A. Bernkop-Schnurch. 2006. Strategies to improve plasma half life time of peptide and protein drugs. Amino Acids 30:351-367.
57. Wheeler, D. A., J. P. Lalezari, J. M. Kilby, J. Wheat, J. Delehanty, R. DeMasi, I. Patel, and M. Salgo. 2004. Safety, tolerability, and plasma pharmacokinetics of high-strength formulations of enfuvirtide (T-20) in treatment-experienced HIV-1-infected patients. J. Clin. Virol. 30:183-190.
58. Wild, C., T. Greenwell, and T. Matthews. 1993. A synthetic peptide from HIV-1 gp41 is a potent inhibitor of virus-mediated cell-cell fusion. AIDS Res. Hum. Retrovir. 9:1051-1053.
59. Zhang, X., K. Nieforth, J. M. Lang, R. Rouzier-Panis, J. Reynes, A. Dorr, S. Kolis, M. R. Stiles, T. Kinchelow, and I. H. Patel. 2002. Pharmacokinetics of plasma enfuvirtide after subcutaneous administration to patients with human immunodeficiency virus: inverse Gaussian density absorption and 2-compartment disposition. Clin. Pharmacol. Ther. 72:10-19.